New-age drug meets resistance
- 1 July 2001
- journal article
- Published by Springer Nature in Nature
- Vol. 412 (6844) , 281-282
- https://doi.org/10.1038/35085665
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of diseaseBritish Journal of Haematology, 2001
- Small-molecule inhibitors of cell signalingCurrent Opinion in Biotechnology, 2000
- Genome changes and gene expression in human solid tumorsCarcinogenesis: Integrative Cancer Research, 2000
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988
- An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activityCell, 1984